Abeona Therapeutics (ABEO) Earns News Sentiment Rating of 0.11

News coverage about Abeona Therapeutics (NASDAQ:ABEO) has trended somewhat positive this week, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Abeona Therapeutics earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.9928847498886 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the media stories that may have impacted Accern Sentiment’s analysis:



Abeona Therapeutics (NASDAQ:ABEO) traded up 0.29% during trading on Friday, reaching $17.45. The company had a trading volume of 438,511 shares. Abeona Therapeutics has a 12 month low of $4.05 and a 12 month high of $22.75. The firm’s 50 day moving average is $16.55 and its 200-day moving average is $9.48. The company’s market capitalization is $703.01 million.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.07). The business had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.21 million. Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. On average, equities analysts expect that Abeona Therapeutics will post ($0.70) earnings per share for the current year.

A number of equities analysts have weighed in on the company. Zacks Investment Research lowered Abeona Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 16th. BidaskClub lowered Abeona Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Royal Bank Of Canada assumed coverage on Abeona Therapeutics in a research note on Thursday, September 14th. They set an “outperform” rating and a $23.00 price objective on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $21.00 price objective on shares of Abeona Therapeutics in a research note on Friday, October 6th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Abeona Therapeutics in a research note on Friday, September 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $22.56.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/27/abeona-therapeutics-abeo-earning-somewhat-positive-news-coverage-report-shows.html.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Insider Buying and Selling by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply